Introduction
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a targeted consultation seeking feedback on proposed updates to the UK medical devices regulatory framework. Among the most notable proposals is the indefinite acceptance of CE-marked medical devices on the Great Britain market.
The consultation invites views from manufacturers, importers, distributors, healthcare professionals and other stakeholders on how the UK should position its regulatory system in the coming years, balancing patient safety, supply continuity and regulatory independence.
Background
Following the UK’s departure from the European Union, CE-marked medical devices have continued to be accepted on the Great Britain market under transitional arrangements. These measures were introduced to avoid disruption to supply while the UK developed its post-Brexit regulatory regime. Under the current framework, CE-marked devices may be placed on the GB market until defined deadlines, after which UKCA marking was expected to become mandatory. These deadlines vary depending on device classification and applicable EU legislation.
The newly published consultation now proposes that CE-marked devices compliant with EU legislation may continue to be accepted on the GB market indefinitely, rather than being subject to a final transition date.
Proposals
Proposal 1: Extend Transitional Arrangements for MDD Devices to Align with EU Timelines
The first proposal concerns devices that comply with the EU Medical Device Directive (MDD). Under the current UK transitional provisions, MDD-certified devices may be placed on the GB market until 30 June 2028 in most cases.
However, the EU has extended its own transitional timelines for certain MDD devices until 31 December 2028. This creates a potential six-month divergence, during which some devices could still be lawfully placed on the EU and Northern Ireland markets under MDD but not on the GB market.
The MHRA is therefore proposing to amend Regulation 19B of the MDR 2002 to align GB timelines with the EU’s updated transitional dates. This would allow eligible MDD devices to be placed on the GB market until 31 December 2028. The intention is to minimise supply disruption and ensure continued patient access during the final phase of transition from MDD to EU MDR.
Proposal 2: Indefinite Recognition of EU MDR and EU IVDR Devices
The second proposal relates to devices certified under the EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR).
Under current arrangements, CE-marked devices compliant with EU MDR or IVDR may be placed on the GB market until 30 June 2030. After that date, UKCA marking would be required.
The consultation proposes extending Regulations 19C and 44ZB indefinitely, allowing continued placement of CE-marked EU MDR and IVDR devices on the GB market without a UK approved body assessment.
Importantly, the MHRA is seeking views on two possible approaches:
- Indefinite recognition for all EU MDR and IVDR devices; or
- Indefinite recognition only for devices that are classified in the same, or lower, risk class under the UK MDR 2002 compared to their EU classification.
The distinction matters because, while classification rules are largely aligned, some devices may be classified at a higher risk category under the UK MDR 2002. Recognition of all devices would effectively accept EU classification decisions in GB. Limiting recognition to devices of the same or lower risk class would preserve the application of UK classification rules where they are stricter.
Even under indefinite recognition, manufacturers or their UK Responsible Person would still be required to register devices with the MHRA and comply with UK post-market surveillance requirements introduced in 2025. They would also be required to notify the MHRA if EU certification is suspended or withdrawn.
The consultation notes that the MHRA does not currently have direct access to notified body surveillance data for CE-marked devices placed on the GB market, which may have implications for regulatory oversight and investigation timelines.
If this proposal is not adopted, the previously consulted international reliance routes would instead be implemented.
Proposal 3: International Reliance Route for Higher-Risk Classifications in GB
The third proposal addresses the small proportion of devices that would be classified at a higher risk category under the UK MDR 2002 than under EU MDR or IVDR. For these devices, the MHRA proposes introducing an international reliance route rather than full UKCA conformity assessment.
Under this route, an approved body in Great Britain would conduct a streamlined review that relies on prior EU conformity assessment. As detailed in Annex B (pages 26–27), this would include confirmation of EU market access, classification verification, confirmation of GB-specific requirements, and review of post-market surveillance plans and recent PMS data.
This route would not result in UKCA marking but would issue a “certificate of international reliance”, allowing the device to be registered and placed on the GB market. Certain self-declared devices that would be up-classified in GB would not be eligible for this route and would instead require full UKCA conformity assessment.
The intention of this proposal is to maintain proportional oversight where UK classification rules are stricter, while avoiding unnecessary duplication of full conformity assessment processes.
The Future of UKCA Marking
Importantly, the UKCA mark is not proposed to be withdrawn. The consultation makes clear that UKCA would remain available as a route to market.
This approach preserves UK regulatory sovereignty and provides the MHRA with the flexibility to introduce UK-specific requirements where considered necessary. Manufacturers would therefore have the option of CE marking alone, or UKCA marking, depending on their regulatory strategy and market priorities.
Editor’s Opinion
The proposal to indefinitely recognise CE-marked devices in Great Britain will inevitably be viewed through the lens of Brexit-era expectations. There was, at the time, considerable discussion about developing a distinctly UK regulatory framework, potentially leaner and more agile than its EU counterpart. For many in the sector, that prospect generated genuine interest in how regulatory reform might evolve.
This consultation suggests a more pragmatic direction. Indefinite recognition of EU MDR and IVDR devices reflects the reality that the overwhelming majority of devices currently placed on the GB market remain CE marked. Requiring full UKCA conformity assessment in parallel would introduce additional regulatory cost and complexity without necessarily improving safety outcomes, particularly where robust EU oversight already exists.
At the same time, the retention of UKCA marking is significant. It preserves the UK’s regulatory autonomy and maintains the legal infrastructure necessary should divergence be considered appropriate in future. The inclusion of an international reliance route for devices classified higher under UK rules further illustrates an attempt to balance access with proportional oversight.
The approach outlined in the consultation appears to prioritise continuity of supply and patient access while maintaining mechanisms for regulatory control. Whether this represents a policy shift or a logical evolution may depend on one’s perspective. What is clear is that the MHRA is seeking structured feedback before finalising its direction, and the outcome will shape the UK’s positioning within the global medical device regulatory landscape for years to come.
Conclusion
The consultation provides stakeholders with the opportunity to submit feedback on the proposed indefinite recognition of CE-marked devices and related regulatory changes. Interested parties are encouraged to review the consultation document in detail and provide responses within the specified timeframe set by the MHRA.
The outcome of this process will shape the future structure of the UK medical devices regulatory landscape, and engagement from across the sector will be central to that direction.